Abstract: The present invention relates to a method for treating degenerative neurological disorders in a subject in need thereof, comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising an acid sphingomyelinase (ASM) activity inhibitor as an active ingredient.

Abstract: A display apparatus includes a display panel, a driving controller and a data driver. The display panel is configured to display an image. The driving controller is configured to generate a compensated image data for compensating a decrease of a luminance of an edge portion of the display panel based on input image data. The data driver is configured to output a data voltage to the display panel based on the compensated image data. The driving controller is configured to generate the compensated image data by comparing a maximum value among subpixel grayscale values of the input image data to which a luminance compensating coefficient is applied and a maximum grayscale value of the input image data. The luminance compensating coefficient is configured to be determined according to a location in the display panel.

Abstract: The present invention relates to a novel peptide exhibiting an effect of releasing myelopoiesis stem cells into blood and an osteoporosis therapeutic effect and use thereof and, in particularly, to a novel peptide consisting of an amino acid sequence of SEQ. ID.NO:1 which has effects of releasing hematopoietic stem cells into a bloodstream and decreasing osteoclast cells in bone narrow, and a pharmaceutical composition comprising the novel peptide as an active ingredient for preventing or treating neutropenia, anemia or osteoporosis. Because of side effects, the peptide of the present invention not only increases level of leukocytes, red blood cells and platelets in blood, but also alleviates a decrease in bone density, and therefore, can be very usefully used for the development of a prophylactic or therapeutic agent for neutropenia, anemia or osteoporosis.

Abstract: The present invention relates to a method for treating degenerative neurological disorders in a subject in need thereof, comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising an acid sphingomyelinase (ASM) activity inhibitor or expression inhibitor as an active ingredient.

Abstract: A flow control valve apparatus switches a circulation direction of cooling medium according to a rotated position of a valve, and a disc provided in the valve controls the flow rate of the cooling medium flowing through a plurality of flow paths, so that the flow rate control of the cooling medium is diversified according to various conditions to improve cooling performance by efficiently circulating the cooling medium.

Abstract: Disclosed is a wing in which, while a continuous surface is maintained, a chord length and camber of an airfoil may be modified via only a rotational drive alone, whereby a structure is simple and aerodynamic efficiency may be improved.

Abstract: A flow control valve apparatus switches a circulation direction of cooling medium according to a rotated position of a valve, and a disc provided in the valve controls the flow rate of the cooling medium flowing through a plurality of flow paths, so that the flow rate control of the cooling medium is diversified according to various conditions to improve cooling performance by efficiently circulating the cooling medium.

Abstract: A display apparatus includes a display panel, a driving controller and a data driver. The driving controller processes input image data according to a variable input frequency and generates a data signal having a varied frame length. The data driver converts the data signal into a data voltage and outputs the data voltage to the display panel. The driving controller determines a variable frequency mode and generates an asymmetric data signal including a positive data signal and a negative data signal which are asymmetric with respect to a common voltage for a same grayscale value in the variable frequency mode.

Abstract: The present invention relates to a composition for diagnosing diseases associated with cyclooxygenase 2 (COX2) overexpression and a screening method therefor and, more particularly, to: a composition for diagnosing diseases associated with COX2 overexpression, containing a compound with a structural feature of exhibiting strong binding activity to a COX2 protein; and a screening method therefor.

Abstract: A display apparatus includes a display panel including a plurality of pixels, and a driver which receives input image data, divides a border portion of the display panel into edge regions and corner regions, generates final image data by compensating the input image data such that luminances of the edge regions are increased by a first multiplicative factor and luminances of the corner regions are increased by a second multiplicative factor greater than the first multiplicative factor, and drives the display panel based on the final image data.

Abstract: The present invention relates to a composition for preventing or treating neurodegenerative diseases or depression, containing a 2-amino-2-(1,2,3-triazole-4-yl)propane-1,3-diol derivative as an active ingredient and more specifically, to a pharmaceutical composition for preventing or treating neurodegenerative diseases or depression, containing, as an active ingredient, the compound having an effect of directly inhibiting ASM activity.

Abstract: A display device includes a display panel comprising a plurality of pixels, a data driver configured to generate data voltages based on a gamma reference voltage, and to provide the data voltages to the plurality of pixels, a gate driver configured to provide gate signals to the plurality of pixels, and a controller configured to control the data driver and the gate driver. The controller is configured to initialize the gamma reference voltage when a blank period starts in a frame period comprising an active period and the blank period, and to change the gamma reference voltage when a duration of the blank period reaches at least one threshold time.

Abstract: A gateway processor of a vehicle includes a controller area network (CAN) message receiver, an Ethernet message receiver, a vehicle state monitoring and recognition unit configured to receive a signal from the CAN message receiver and the Ethernet message receiver, and a power management determination unit for each state configured to receive a signal from the vehicle state monitoring and recognition unit. The gateway processor also includes an electronic control unit (ECU) power control application execution unit configured to receive a signal from the power management determination unit for each state.

Abstract: The present invention relates to a pharmaceutical composition containing stem cells in which vascular endothelial growth factor (VEGF) is overexpressed as an effective ingredient for preventing or treating neurodegenerative diseases. The stem cells in which VEGF is overexpressed according to the present invention effectively act against the neurodegenerative disease-induced VEGF reduction of neural stem cells in the SVC to inhibit the abnormal migration of neural stem cells, suppress inflammatory responses, and restrain the accumulation of cholesterol and spingolipids in the cerebral cortex, thus restoring the behavior exercise capacity of animal models, whereby the pharmaceutical composition can be used as an effective therapeutic agent for neurodegenerative diseases.

Abstract: The present invention relates to a novel use for HDL-ApoM-S1P (a high density lipoprotein in which apolipoprotein M is impregnated with sphingosine-1-phosphate), and more particularly, to using HDL-ApoM-S1P to prevent, improve, or treat degenerative brain disorders (in particular, Alzheimer's disease), cognitive disorders, learning disabilities, and memory disorders, and using HDL-ApoM-S1P to improve cognitive ability, learning ability, and memory. The HDL-ApoM-S1P according to the present invention not only alleviates neuroinflammation but also significantly exhibits improvement effects of cognitive disorder, learning disability, and memory disorder with respect to individuals suffering from degenerative brain disorders (in particular, Alzheimer's disease), and exhibits an effect of greatly reducing amyloid beta and tau deposition. Moreover, increased HDL-ApoM-S1P in the body also has an excellent effect of improving the cognitive, learning, and memory abilities of non-disabled individuals.

Abstract: The present invention relates to a novel phenylsulfonyl oxazole derivative and a use thereof and specifically, to a compound represented by Chemical Formula 1 in the present specification or a pharmaceutically acceptable salt thereof, and to a use thereof for prevention, treatment, or improvement of neurodegenerative disease.

Abstract: The present invention relates to a composition for diagnosis of degenerative neurological diseases and, more specifically, to a composition for diagnosis of degenerative neurological diseases, comprising an agent for measuring the level of acetylation of COX2. According to the present invention, since acetylation of COX2 in degenerative neurological diseases is significantly reduced, whether COX2 is acetylated may be utilized as a diagnostic marker for degenerative neurological diseases, and it is possible to diagnose degenerative neurological diseases more rapidly and accurately by using same.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating neurodegenerative diseases comprising a COX2 acetylating agent as an active ingredient and, more particularly, to a pharmaceutical composition for preventing or treating neurodegenerative diseases comprising, as an active ingredient, a COX2 acetylating agent which exhibits an effect of inhibiting the deposition of amyloid-? in brain neurons, reducing excessive neuroinflammatory responses, and increasing the phagocytosis of amyloid-? in microglial cells. The pharmaceutical composition for preventing or treating neurodegenerative diseases comprising the COX2 acetylating agent as an active ingredient has the effects of alleviating neuroinflammation by promoting COX2 acetylation in neurons and secreting specialized pro-resolving mediators (SPMs) and thus, can be very useful in the development of a preventive or therapeutic agent for neurodegenerative diseases.

Abstract: A display apparatus includes a display panel, a driving controller and a data driver. The display panel is configured to display an image. The driving controller is configured to generate a compensated image data for compensating a decrease of a luminance of an edge portion of the display panel based on input image data. The data driver is configured to output a data voltage to the display panel based on the compensated image data. The driving controller is configured to generate the compensated image data by comparing a maximum value among subpixel grayscale values of the input image data to which a luminance compensating coefficient is applied and a maximum grayscale value of the input image data. The luminance compensating coefficient is configured to be determined according to a location in the display panel.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating neurodegenerative disease, containing, as active ingredients, cyclodextrin and stem cells in which VEGF is overexpressed. A combined treatment of cyclodextrin and stem cells in which VEGF is overexpressed has remarkable synergistic effects, with respect to therapeutic efficacy on the disease, such as a lifespan increase, mobility improvement, inhibition of neurogenic inflammation, inhibition of nerve cell apoptosis and inhibition of lipid accumulation in organs, including the brain, on a neurodegenerative disease model, thereby presenting a novel therapeutic strategy.